Melanoma Clinical Trials in Georgia

Cancer Type = Melanoma

Cancer Type = Melanoma

There are currently 26 active Melanoma clinical trials in Georgia.
2.
A Multi-site, Prospective, Observational Study in US Patients with Advanced Melanoma
Cancer Type
Melanoma
NCI ID
Protocol IDs
CA184-199
IMPULSE
BMS CA184-199
5.
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Eye Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03849469
Protocol IDs
XmAb22841-01
NCI-2019-02498
DUET-4
6.
A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03415126
Protocol IDs
ASN007-101
NCI-2018-00820
7.
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies.
Cancer Type
Kidney Cancer, Lung Cancer, Melanoma
NCI ID
NCT02983045
Protocol IDs
16-214-02
NCI-2017-00053
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
A Phase 1b / 2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies
Cancer Type
Breast Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT02554812
Protocol IDs
B9991004
NCI-2015-02263
2015-002552-27
JAVELIN MEDLEY
s16-02110
9.
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03635983
Protocol IDs
CA045-001
NCI-2018-02224
17-214-08
2018-001423-40
10.
A Phase I / 2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Cancer Type
Bladder Cancer, Cervical Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT01968109
Protocol IDs
CA224-020
NCI-2014-00315
2014-002605-38
12.
NCORP Trial
A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)
Cancer Type
Bone and Soft Tissue (including Sarcoma), Melanoma
NCI ID
NCT02775851
Protocol IDs
S1512
NCI-2016-00666
13.
NCORP Trial
A Phase II Randomized Study of Adjuvant versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma)
NCI ID
NCT03698019
Protocol IDs
S1801
S1801
NCI-2018-02107
Treatment Sites (1)
15.
A Randomized Phase 2 Study of Rituxan Hycela in Patients with Advanced Melanoma Undergoing Combination Immune Checkpoint Blockade with Nivolumab and Ipilimumab
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma)
NCI ID
NCT03719131
Protocol IDs
Winship4457-18
NCI-2018-01804
IRB00105605
16.
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03445533
Protocol IDs
2125-MEL-301
NCI-2018-00422
17.
NCORP Trial
A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Cancer Type
Melanoma, Unknown Primary
NCI ID
NCT02224781
Protocol IDs
EA6134
NCI-2014-01747
Treatment Sites (14)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
20.
NCORP Trial
Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma)
NCI ID
NCT03553836
Protocol IDs
3475-716
NCI-2018-01981
2018-000669-35
MK-3475-716
KEYNOTE 716
Treatment Sites (13)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
21.
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 in Patients With Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma
Cancer Type
Colon/Rectal Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03809624
Protocol IDs
Ph 1 INBRX-105
NCI-2019-02844
22.
NCORP Trial
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Stable or Slowly Progressing Disease.
Cancer Type
Melanoma
NCI ID
NCT02678741
Protocol IDs
20152397
NCI-2016-01327
Treatment Sites (5)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
23.
Phase I / II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy
Cancer Type
Kidney Cancer, Lung Cancer, Melanoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03656718
Protocol IDs
CA209-8KX
NCI-2018-02324
2018-001585-42
24.
Pilot Integrated Biomarker Study of VX15 / 2503 in Combination with Ipilimumab or Nivolumab in Patients with Resectable Metastatic Melanoma
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma)
NCI ID
NCT03769155
Protocol IDs
Winship4400-18
NCI-2018-01229
IRB00104273
25.
Rad3179-16 (MK-3475-423) Pilot Study of Pembrolizumab and Stereotactic Radio-Surgery (SRS) for Patients with Melanoma or Non-small Cell Lung Cancer (NSCLC) Brain Metastases (BM)
Cancer Type
Eye Cancer, Lung Cancer, Melanoma, Unknown Primary
NCI ID
NCT02858869
Protocol IDs
RAD3179-16
NCI-2016-00718
IRB00086461
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.